Literature DB >> 23219038

US-guided optical tomography: correlation with clinicopathologic variables in breast cancer.

Ji Soo Choi1, Min Jung Kim, Ji Hyun Youk, Hee Jung Moon, Hee Jung Suh, Eun-Kyung Kim.   

Abstract

We tested the relationships between total hemoglobin concentration (THC), as measured with ultrasound (US)-guided optical tomography, and clinicopathologic variables in invasive ductal cancers; and we evaluated the clinical significance of THC. Fifty-three patients with 65 invasive ductal carcinomas underwent US-guided biopsy and were scanned with a hand-held probe consisting of a co-registered US transducer and an NIR (near-infrared) imager. The lesion location provided by co-registered US was used to guide optical imaging. Light absorption was measured at two optical wavelengths. From this measurement, tumor angiogenesis was assessed on the basis of calculated THC. We investigated the relationships between maximum THC and clinicopathologic variables (tumor size [≤2 cm or >2 cm], metastasis to lymph node or distant organ, histologic grade, lymphovascular invasion, status of ER, PR, HER2 and Ki-67, and triple negativity). The mean maximum THC in the breast cancers was 223.3 ± 106.3 μmol/L. In univariate analysis, HER2 positivity, tumor size, and Ki-67 positivity showed significant correlations with maximum THC (p < 0.05). In multivariate analysis including tumor size, and ER, PR, HER2, and Ki-67 status, HER2 positivity correlated with maximum THC significantly (p = 0.007, parameter estimate 76.44). Maximum THC correlated with HER2, Ki-67 and tumor size in this group of ductal breast carcinomas. Thus, US-guided diffuse optical tomography (US-DOT) may potentially be used to predict tumor aggressiveness in patients with invasive breast cancers.
Copyright © 2013 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219038     DOI: 10.1016/j.ultrasmedbio.2012.09.014

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  7 in total

1.  Emerging Breast Imaging Technologies on the Horizon.

Authors:  Srinivasan Vedantham; Andrew Karellas
Journal:  Semin Ultrasound CT MR       Date:  2017-09-13       Impact factor: 1.875

Review 2.  A review of optical breast imaging: Multi-modality systems for breast cancer diagnosis.

Authors:  Quing Zhu; Steven Poplack
Journal:  Eur J Radiol       Date:  2020-05-18       Impact factor: 3.528

3.  Optimal breast cancer diagnostic strategy using combined ultrasound and diffuse optical tomography.

Authors:  K M Shihab Uddin; Menghao Zhang; Mark Anastasio; Quing Zhu
Journal:  Biomed Opt Express       Date:  2020-04-24       Impact factor: 3.732

4.  Effect of vascular haemoglobin concentrations on ultrasound-guided diffuse optical tomography in differentiating benign from malignant breast lesions.

Authors:  Ning Lv; Ni He; Yaopan Wu; Chuanmiao Xie; Yue Wang; Yanan Kong; Weidong Wei; Peihong Wu
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

5.  Assessment of Functional Differences in Malignant and Benign Breast Lesions and Improvement of Diagnostic Accuracy by Using US-guided Diffuse Optical Tomography in Conjunction with Conventional US.

Authors:  Quing Zhu; Andrew Ricci; Poornima Hegde; Mark Kane; Edward Cronin; Alex Merkulov; Yan Xu; Behnoosh Tavakoli; Susan Tannenbaum
Journal:  Radiology       Date:  2016-03-02       Impact factor: 11.105

6.  US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.

Authors:  Min Jung Kim; Min-Ying Su; Hon J Yu; Jeon-Hor Chen; Eun-Kyung Kim; Hee Jung Moon; Ji Soo Choi
Journal:  BMC Cancer       Date:  2016-02-01       Impact factor: 4.430

7.  US-guided Diffuse Optical Tomography: Clinicopathological Features Affect Total Hemoglobin Concentration in Breast Cancer.

Authors:  Wenxiang Zhi; Yu Wang; Cai Chang; Fen Wang; Yaling Chen; Na Hu; Xiaoli Zhu; Li Xie
Journal:  Transl Oncol       Date:  2018-05-09       Impact factor: 4.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.